1.545  -0.015 (-0.96%)		10-15 12:14
Open: 1.55 High: 1.5899 Volume: 196,959		Pre. Close: 1.56 Low: 1.535 Market Cap: 48(M)

Short term
Mid term
Targets	6-month :	1.88	1-year :	1.98
Resists	First :	1.61	Second :	1.7
Pivot price	1.57
Supports	First :	1.47	Second :	1.22
MAs	MA(5) :	1.54	MA(20) :	1.58
	MA(100) :	1.61	MA(250) :	1.48
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	48.4	D(3) :	37.9
RSI	RSI(14): 44.6
52-week	High :	2.41	Low :	1.02

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ATNM ] has closed above bottom band by 32.1%. Bollinger Bands are 55.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.61 - 1.62	1.62 - 1.63
Low:	1.5 - 1.52	1.52 - 1.53
Close:	1.54 - 1.56	1.56 - 1.58

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Mon, 13 Oct 2025
Actinium Pharmaceuticals (ATNM) Reveals Promising Data for NSCLC Treatment - GuruFocus

Mon, 13 Oct 2025
Actinium Shares Rise After Preclinical Data for ATNM-400 Show Potent Anti-Tumor Activity in Lung Cancer Models - MarketScreener

Mon, 13 Oct 2025
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeut - PR Newswire

Mon, 13 Oct 2025
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - Yahoo Finance

Sun, 21 Sep 2025
Actinium Pharmaceuticals, Inc.(NYSEAM: ATNM) dropped from S&P Global BMI Index - MarketScreener

Tue, 02 Sep 2025
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	31 (M)
Held by Insiders	3.037e+007 (%)
Held by Institutions	2 (%)
Shares Short	2,470 (K)
Shares Short P.Month	0 (K)

EPS	-4.648e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-57 %
Return on Assets (ttm)	665.4 %
Return on Equity (ttm)	-31 %
Qtrly Rev. Growth	81000 %
Gross Profit (p.s.)	0
Sales Per Share	-586.4
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1.6 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-34 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	0.16

Dividend	0
Forward Dividend	2.22e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.